Pacira Pharmaceuticals diskutieren
Pacira Pharmaceuticals
WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Aktie / Pharmazeutika / Small Cap /
25,00 €
3,31 %
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Needham & Company LLC from $63.00 to $60.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $80.00 to $76.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Needham & Company LLC from $60.00 to $52.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $70.00 to $68.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $60.00 to $57.00. They now have an "overweight" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $67.00 to $58.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at HC Wainwright from $63.00 to $57.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) is now covered by analysts at Raymond James. They set an "outperform" rating and a $42.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $53.00 to $45.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $45.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Neueste Beiträge
Benchmark_Co_ in Codexis Inc. diskutieren